The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Human Alpha1-Proteinase Inhibitor Market Research Report 2025
Synopsis
Alpha1-Proteinase Inhibitor (Human), is a sterile, stable, lyophilized preparation of highly purified human alpha1-proteinase inhibitor (A1-PI)
The global Human Alpha1-Proteinase Inhibitor market was valued at US$ 218 million in 2023 and is anticipated to reach US$ 293.1 million by 2030, witnessing a CAGR of 4.2% during the forecast period 2024-2030.
The market growth can be attributed to several factors. Firstly, increasing awareness and improved diagnosis of AATD have led to a better identification of patients with this condition, driving the demand for Alpha1-PI therapy. Additionally, advancements in biotechnology and protein manufacturing techniques have contributed to the development of highly purified and more effective Alpha1-PI products, offering improved treatment options for patients.
This report aims to provide a comprehensive presentation of the global market for Human Alpha1-Proteinase Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Alpha1-Proteinase Inhibitor.
Report Scope
The Human Alpha1-Proteinase Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Alpha1-Proteinase Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Alpha1-Proteinase Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Kamada
Grifols
CSL Behring
Segment by Type
0.5g
1g
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Alpha1-Proteinase Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Alpha1-Proteinase Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Alpha1-Proteinase Inhibitor (Human), is a sterile, stable, lyophilized preparation of highly purified human alpha1-proteinase inhibitor (A1-PI)
The global Human Alpha1-Proteinase Inhibitor market was valued at US$ 218 million in 2023 and is anticipated to reach US$ 293.1 million by 2030, witnessing a CAGR of 4.2% during the forecast period 2024-2030.
The market growth can be attributed to several factors. Firstly, increasing awareness and improved diagnosis of AATD have led to a better identification of patients with this condition, driving the demand for Alpha1-PI therapy. Additionally, advancements in biotechnology and protein manufacturing techniques have contributed to the development of highly purified and more effective Alpha1-PI products, offering improved treatment options for patients.
This report aims to provide a comprehensive presentation of the global market for Human Alpha1-Proteinase Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Alpha1-Proteinase Inhibitor.
Report Scope
The Human Alpha1-Proteinase Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Alpha1-Proteinase Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Alpha1-Proteinase Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Kamada
Grifols
CSL Behring
Segment by Type
0.5g
1g
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Alpha1-Proteinase Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Alpha1-Proteinase Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Human Alpha1-Proteinase Inhibitor Market Overview
1.1 Product Overview and Scope of Human Alpha1-Proteinase Inhibitor
1.2 Human Alpha1-Proteinase Inhibitor Segment by Type
1.2.1 Global Human Alpha1-Proteinase Inhibitor Market Value Comparison by Type (2024-2030)
1.2.2 0.5g
1.2.3 1g
1.3 Human Alpha1-Proteinase Inhibitor Segment by Application
1.3.1 Global Human Alpha1-Proteinase Inhibitor Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Global Human Alpha1-Proteinase Inhibitor Market Size Estimates and Forecasts
1.4.1 Global Human Alpha1-Proteinase Inhibitor Revenue 2019-2030
1.4.2 Global Human Alpha1-Proteinase Inhibitor Sales 2019-2030
1.4.3 Global Human Alpha1-Proteinase Inhibitor Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Human Alpha1-Proteinase Inhibitor Market Competition by Manufacturers
2.1 Global Human Alpha1-Proteinase Inhibitor Sales Market Share by Manufacturers (2019-2024)
2.2 Global Human Alpha1-Proteinase Inhibitor Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Human Alpha1-Proteinase Inhibitor Average Price by Manufacturers (2019-2024)
2.4 Global Human Alpha1-Proteinase Inhibitor Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Alpha1-Proteinase Inhibitor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Alpha1-Proteinase Inhibitor, Product Type & Application
2.7 Human Alpha1-Proteinase Inhibitor Market Competitive Situation and Trends
2.7.1 Human Alpha1-Proteinase Inhibitor Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Alpha1-Proteinase Inhibitor Players Market Share by Revenue
2.7.3 Global Human Alpha1-Proteinase Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Alpha1-Proteinase Inhibitor Retrospective Market Scenario by Region
3.1 Global Human Alpha1-Proteinase Inhibitor Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Human Alpha1-Proteinase Inhibitor Global Human Alpha1-Proteinase Inhibitor Sales by Region: 2019-2030
3.2.1 Global Human Alpha1-Proteinase Inhibitor Sales by Region: 2019-2024
3.2.2 Global Human Alpha1-Proteinase Inhibitor Sales by Region: 2025-2030
3.3 Global Human Alpha1-Proteinase Inhibitor Global Human Alpha1-Proteinase Inhibitor Revenue by Region: 2019-2030
3.3.1 Global Human Alpha1-Proteinase Inhibitor Revenue by Region: 2019-2024
3.3.2 Global Human Alpha1-Proteinase Inhibitor Revenue by Region: 2025-2030
3.4 North America Human Alpha1-Proteinase Inhibitor Market Facts & Figures by Country
3.4.1 North America Human Alpha1-Proteinase Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Human Alpha1-Proteinase Inhibitor Sales by Country (2019-2030)
3.4.3 North America Human Alpha1-Proteinase Inhibitor Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.4.6 Mexico
3.5 Europe Human Alpha1-Proteinase Inhibitor Market Facts & Figures by Country
3.5.1 Europe Human Alpha1-Proteinase Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Human Alpha1-Proteinase Inhibitor Sales by Country (2019-2030)
3.5.3 Europe Human Alpha1-Proteinase Inhibitor Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Alpha1-Proteinase Inhibitor Market Facts & Figures by Country
3.6.1 Asia Pacific Human Alpha1-Proteinase Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Human Alpha1-Proteinase Inhibitor Sales by Country (2019-2030)
3.6.3 Asia Pacific Human Alpha1-Proteinase Inhibitor Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Human Alpha1-Proteinase Inhibitor Market Facts & Figures by Country
3.7.1 Latin America Human Alpha1-Proteinase Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Human Alpha1-Proteinase Inhibitor Sales by Country (2019-2030)
3.7.3 Latin America Human Alpha1-Proteinase Inhibitor Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Alpha1-Proteinase Inhibitor Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Alpha1-Proteinase Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Human Alpha1-Proteinase Inhibitor Sales by Country (2019-2030)
3.8.3 Middle East and Africa Human Alpha1-Proteinase Inhibitor Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Alpha1-Proteinase Inhibitor Sales by Type (2019-2030)
4.1.1 Global Human Alpha1-Proteinase Inhibitor Sales by Type (2019-2024)
4.1.2 Global Human Alpha1-Proteinase Inhibitor Sales by Type (2025-2030)
4.1.3 Global Human Alpha1-Proteinase Inhibitor Sales Market Share by Type (2019-2030)
4.2 Global Human Alpha1-Proteinase Inhibitor Revenue by Type (2019-2030)
4.2.1 Global Human Alpha1-Proteinase Inhibitor Revenue by Type (2019-2024)
4.2.2 Global Human Alpha1-Proteinase Inhibitor Revenue by Type (2025-2030)
4.2.3 Global Human Alpha1-Proteinase Inhibitor Revenue Market Share by Type (2019-2030)
4.3 Global Human Alpha1-Proteinase Inhibitor Price by Type (2019-2030)
5 Segment by Application
5.1 Global Human Alpha1-Proteinase Inhibitor Sales by Application (2019-2030)
5.1.1 Global Human Alpha1-Proteinase Inhibitor Sales by Application (2019-2024)
5.1.2 Global Human Alpha1-Proteinase Inhibitor Sales by Application (2025-2030)
5.1.3 Global Human Alpha1-Proteinase Inhibitor Sales Market Share by Application (2019-2030)
5.2 Global Human Alpha1-Proteinase Inhibitor Revenue by Application (2019-2030)
5.2.1 Global Human Alpha1-Proteinase Inhibitor Revenue by Application (2019-2024)
5.2.2 Global Human Alpha1-Proteinase Inhibitor Revenue by Application (2025-2030)
5.2.3 Global Human Alpha1-Proteinase Inhibitor Revenue Market Share by Application (2019-2030)
5.3 Global Human Alpha1-Proteinase Inhibitor Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Takeda
6.1.1 Takeda Corporation Information
6.1.2 Takeda Description and Business Overview
6.1.3 Takeda Human Alpha1-Proteinase Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Takeda Human Alpha1-Proteinase Inhibitor Product Portfolio
6.1.5 Takeda Recent Developments/Updates
6.2 Kamada
6.2.1 Kamada Corporation Information
6.2.2 Kamada Description and Business Overview
6.2.3 Kamada Human Alpha1-Proteinase Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Kamada Human Alpha1-Proteinase Inhibitor Product Portfolio
6.2.5 Kamada Recent Developments/Updates
6.3 Grifols
6.3.1 Grifols Corporation Information
6.3.2 Grifols Description and Business Overview
6.3.3 Grifols Human Alpha1-Proteinase Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Grifols Human Alpha1-Proteinase Inhibitor Product Portfolio
6.3.5 Grifols Recent Developments/Updates
6.4 CSL Behring
6.4.1 CSL Behring Corporation Information
6.4.2 CSL Behring Description and Business Overview
6.4.3 CSL Behring Human Alpha1-Proteinase Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.4.4 CSL Behring Human Alpha1-Proteinase Inhibitor Product Portfolio
6.4.5 CSL Behring Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Alpha1-Proteinase Inhibitor Industry Chain Analysis
7.2 Human Alpha1-Proteinase Inhibitor Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Alpha1-Proteinase Inhibitor Production Mode & Process
7.4 Human Alpha1-Proteinase Inhibitor Sales and Marketing
7.4.1 Human Alpha1-Proteinase Inhibitor Sales Channels
7.4.2 Human Alpha1-Proteinase Inhibitor Distributors
7.5 Human Alpha1-Proteinase Inhibitor Customers
8 Human Alpha1-Proteinase Inhibitor Market Dynamics
8.1 Human Alpha1-Proteinase Inhibitor Industry Trends
8.2 Human Alpha1-Proteinase Inhibitor Market Drivers
8.3 Human Alpha1-Proteinase Inhibitor Market Challenges
8.4 Human Alpha1-Proteinase Inhibitor Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
